{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:34Z","timestamp":1761100534064},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":322,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,2]]},"abstract":"<jats:p>Ten patients with polycythaemia vera (PV) and nine with essential thrombocythaemia (ET) received a haemopoietic stem cell transplant (HSCT) at the Fred Hutchinson Cancer Research Center between May 1988 and March 2000. HSCT was performed because of progression to the spent phase of the disease with myelofibrosis and splenomegaly in 10 patients and evolution into a myelodysplastic syndrome (MDS) or acute myelogenous leukaemia (AML) in nine patients. Patients were 18\u201359\u2003years old (median 43). The interval from diagnosis to HSCT was 77\u2013300\u2003months (median 170). Seven patients were splenectomized before transplantation, and all but five had been treated with cytotoxic agents. Eleven patients received a transplant from a related, and eight from an unrelated, donor following conditioning with chemotherapy only or chemotherapy plus total body irradiation regimens. All evaluable patients achieved sustained engraftment. Twelve patients are surviving 5\u2013116\u2003months (median 41) after transplant, 10 in continued complete remission, one in haematological remission with residual marrow fibrosis and one with mixed haemopoietic chimaerism currently receiving therapy with interferon. Seven patients (six with AML\/MDS and one with myelofibrosis) died of transplant\u2010related complications. These data show that HSCT can provide curative therapy for patients with PV and ET with advanced disease.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02584.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:31:08Z","timestamp":1047364268000},"page":"392-396","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia"],"prefix":"10.1111","volume":"112","author":[{"given":"M.","family":"Jurado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Chauncey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E. D.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Storb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. R.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3083125.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"e_1_2_6_6_1","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk P.D.","year":"1986","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4"},{"key":"e_1_2_6_8_1","first-page":"319","volume-title":"Clinical Haematology","author":"Clift R.A.","year":"1997"},{"key":"e_1_2_6_9_1","first-page":"681","volume-title":"Clinical Bone Marrow and Blood Stem Cell Transplantation","author":"Deeg H.J.","year":"2000"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.10.3880"},{"key":"e_1_2_6_11_1","first-page":"187","article-title":"Allogeneic bone marrow transplantation for postpolycythemic myeloid metaplasia with myelofibrosis: a case report","volume":"16","author":"De Revel T.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61011-8"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.12.4531"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V82.7.2235.2235","article-title":"Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase","volume":"82","author":"Goldman J.M.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-9-199511010-00003"},{"key":"e_1_2_6_16_1","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano Per Il Trapianto Del Midollo Osseo and Fred Hutchinson Cancer Research Center collaborative study","volume":"93","author":"Guardiola P.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_18_1","first-page":"167","article-title":"Long\u2010term management of polycythemia vera with hydroxyurea: a progress report","volume":"23","author":"Kaplan M.E.","year":"1986","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074371"},{"key":"e_1_2_6_20_1","first-page":"519a","article-title":"Outpatient PBSC allografts using immunosuppression with low\u2010dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant","volume":"92","author":"McSweeney P.A.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_21_1","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy S.","year":"1986","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_22_1","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy S.","year":"1997","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074372"},{"key":"e_1_2_6_24_1","first-page":"1","volume-title":"Agnogenic Myeloid Metaplasia","author":"Silverstein M.N.","year":"1975"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.756"},{"key":"e_1_2_6_26_1","first-page":"337","article-title":"Allogeneic bone marrow transplantation for an adolescent with polycythemia vera","volume":"13","author":"Stobart K.","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141201"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.2.267.267"},{"key":"e_1_2_6_29_1","first-page":"1","volume-title":"Histopathologie de la Moelle Osseuse: Indications et Interpr\u00e9tation de la Biopsie M\u00e9dullaire","author":"Sultan C.","year":"1991"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04853.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2226"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02584.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02584.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02584.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T22:08:46Z","timestamp":1697580526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02584.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02584.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02584.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}